Tumor markers in non-small cell lung cancer spine metastasis: an assessment of prognosis and overall survival

被引:0
|
作者
Foresi, Brian [1 ]
Shah, Aakash [2 ]
Meade, Seth [2 ]
Krishnaney, Ajit [3 ]
机构
[1] Northeast Ohio Med Univ NEOMED, Coll Med, Rootstown, OH 44272 USA
[2] Case Western Reserve Univ, Coll Med, Cleveland, OH USA
[3] Cleveland Clin, Dept Neurosurg, Cleveland, OH USA
关键词
Non-small cell lung cancer; Metastasis; Spine; Tumor markers; Prognosis; Overall survival; PREOPERATIVE EVALUATION; SCORING SYSTEM; BONE;
D O I
10.1007/s00586-024-08447-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
PurposeThe identification of gene mutations in the modern medical workup of metastatic spine tumors has become more common but has not been highly utilized in surgical planning. Potential utility of these genetic markers as surrogates for cancer behavior in current prognosis scoring systems and overall survival (OS) remains underexplored in existing literature. This study seeks to investigate the association of frequently identified tumor markers, EGFR, ALK, and PD-L1, in metastatic non-small cell lung cancer (NSCLC) to the spine with Tokuhashi prognosis scoring and OS.MethodsPatients with NSCLC metastasis to spine were identified through chart review. EGFR, ALK, and PD-L1 wild type vs. mutant type were identified from targeted chemotherapy genetic testing. Multiple linear regression was performed to assess gene profile contributions to Tokuhashi score. Cox Proportional Hazards models were generated for each tumor marker to assess the relationship between each marker and OS.ResultsA total of 119 patients with NSCLC spine metastasis were identified. We employed a multiple linear regression analysis to investigate the influence of EGFR, ALK, and PD-L1 genotypes on the Tokuhashi score, revealing statistically significant relationships overall (p = 0.002). Individual genotype contributions include EGFR as a non-significant contributor (p = 0.269) and ALK and PD-L1 as significant contributors (p = 0.037 and p = 0.001 respectively). Overall survival was not significantly associated with tumor marker profiles through Kaplan-Meier analysis (p = 0.46) or by multivariable analysis (p = 0.108).ConclusionALK and PD-L1 were significantly associated with Tokuhashi score while EGFR was not. Tumor markers alone were not predictive of OS. These findings indicate that genetic markers found in NSCLC metastases to the spine may demonstrate prognostic value. Therefore, employing standard tumor markers could enhance the identification of appropriate surgical candidates, although they demonstrate limited effectiveness in predicting overall survival.
引用
收藏
页码:4346 / 4352
页数:7
相关论文
共 50 条
  • [41] Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer
    Jiang, Long
    Zhao, Zerui
    Jiang, Shanshan
    Lin, Yongbin
    Yang, Han
    Xie, Zehua
    Lin, Yaobin
    Long, Hao
    IMMUNOLOGIC RESEARCH, 2015, 62 (03) : 316 - 324
  • [42] MARKERS OF PROGNOSIS IN RESECTED STAGE IB NON-SMALL CELL LUNG CANCER (NSCLC)
    Yip, Po Yee
    Cooper, Wendy
    Mahar, Annabelle
    Kench, James
    Kohonen-Corish, Maija R. J.
    Chatfield, Mark
    Boulghourjian, Alice
    Kennedy, Catherine W.
    Mccaughan, Brian
    Boyer, Michael
    Horvath, Lisa
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S499 - S499
  • [43] Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer
    Long Jiang
    Zerui Zhao
    Shanshan Jiang
    Yongbin Lin
    Han Yang
    Zehua Xie
    Yaobin Lin
    Hao Long
    Immunologic Research, 2015, 62 : 316 - 324
  • [44] Immunological Markers Predict the Prognosis of Patients with Squamous Non-Small Cell Lung Cancer
    Jiang, Long
    Jiang, Shanshan
    Long, Hao
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S268 - S268
  • [45] Perianal Metastasis of Non-Small Cell Lung Cancer
    Imai, Hisao
    Inafuku, Kenji
    Wakuda, Kazushige
    Ono, Akira
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Watanabe, Reiko
    Naito, Tateaki
    Murakami, Haruyasu
    Ito, Ichiro
    Endo, Masahiro
    Tanabe, Hiroyasu
    Nakajima, Takashi
    Takahashi, Toshiaki
    INTERNAL MEDICINE, 2014, 53 (11) : 1149 - 1152
  • [46] Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer
    Nieder, C
    Andratschke, N
    Jeremic, B
    Molls, M
    ANTICANCER RESEARCH, 2003, 23 (6D) : 5117 - 5123
  • [47] Markers of tumor invasion as predictors of survival after resection of non-small cell lung cancer in stage I
    Klein, J
    Kral, V
    Tichy, T
    Neoral, C
    Bohanes, T
    Drac, P
    Skarda, J
    Rihakova, P
    Grygarkova, I
    Kolar, Z
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 419 - 419
  • [48] Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib
    Chiu, Chao-Hua
    Shih, Yu-Ning
    Tsai, Chun-Ming
    Liou, Jia-Ling
    Chen, Yuh-Min
    Perng, Reury-Perng
    LUNG CANCER, 2007, 57 (02) : 213 - 221
  • [49] Lung cancer with cavitation: A distinct subgroup of non-small cell lung cancer associated with poor overall survival
    Singh, Navneet
    Behera, Digambar
    RESPIRATORY INVESTIGATION, 2015, 53 (03) : 133 - 134
  • [50] Tumor hypoxia and metastasis in non-small cell lung cancers
    Le, Quynh-thu
    Erler, Janine T.
    Giaccia, Amato
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S154 - S155